Allosteric interactions at adenosineA1andA3receptors: new insights into the role of small molecules and receptor dimerization
Open Access
- 27 February 2014
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (5) , 1102-1113
Abstract
The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specificGPCRsto either stimulate cyclicAMPformation, as exemplified byGs‐protein‐coupled adenosine receptors (A2AandA2B), or inhibit AC activity, in the case ofGi/o‐coupled adenosine receptors (A1andA3). Recent advances in our understanding ofGPCRstructure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosineA1andA3receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single‐cell ligand‐binding kinetics and the effects ofA1‐ andA3‐receptor allosteric modulators onin vivopharmacology.Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visithttp://dx.doi.org/10.1111/bph.2014.171.issue‐5Keywords
This publication has 115 references indexed in Scilit:
- A1R–A2AR heteromers coupled to Gs and Gi/0 proteins modulate GABA transport into astrocytesPurinergic Signalling, 2013
- Functional selectivity of adenosine A1 receptor ligands?Purinergic Signalling, 2012
- New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptorsPurinergic Signalling, 2012
- Pharmacological and therapeutic effects of A3 adenosine receptor agonistsDrug Discovery Today, 2012
- Partial adenosine A1 receptor agonists for cardiovascular therapiesPurinergic Signalling, 2011
- Functionally biased modulation of A3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancersBiochemical Pharmacology, 2011
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Allosteric Modulation of Purine and Pyrimidine Receptors2011
- CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liverJournal of Cellular Physiology, 2010
- Introduction to Adenosine Receptors as Therapeutic Targets2009